Actuate Therapeutics IncACTUNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +25.99% | +27.87% | +25.88% | +0.59% | +9.64% |
| Weighted Average Shares Diluted Growth | +25.99% | +27.87% | +25.88% | +0.59% | +9.64% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +0.00% | +211.07% | +66.13% | +302.63% | +24.20% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +86.15% |
| Debt Growth | +0.00% | +0.00% | -100.00% | -100.00% | +0.00% |
| R&D Expense Growth | -34.79% | -44.54% | -53.06% | -36.77% | -42.03% |
| SG&A Expenses Growth | +129.05% | +196.40% | +244.56% | +201.52% | +101.40% |